MedTrace Logo

Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux

NCT00864396 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2017-03-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR).

Conditions

  • Laryngopharyngeal Reflux

Interventions

DRUG

Prevacid

30mg of Lansoprazole twice daily (or placebo)for eight weeks.

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Peter Belafsky, MD, Ph.D. · University of California, Davis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00864396 on ClinicalTrials.gov